Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer

The ongoing, Phase Ib MONALEESASIA study is evaluating the efficacy and safety of ribociclib plus endocrine therapy in Asian patients with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer. Eligible patients from Japan, Hong Kong, and Singapore were...

Descripción completa

Detalles Bibliográficos
Autores principales: Yap, Yoon‐Sim, Chiu, Joanne, Ito, Yoshinori, Ishikawa, Takashi, Aruga, Tomoyuki, Kim, Seung Jin, Toyama, Tatsuya, Saeki, Toshiaki, Saito, Mitsue, Gounaris, Ioannis, Su, Fei, Ji, Yan, Han, Yu, Gazdoiu, Mihaela, Masuda, Norikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469771/
https://www.ncbi.nlm.nih.gov/pubmed/32619077
http://dx.doi.org/10.1111/cas.14554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469771/
https://www.ncbi.nlm.nih.gov/pubmed/32619077
http://dx.doi.org/10.1111/cas.14554

Ejemplares similares